LP
AST

LMR Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

LMR Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,168
Closed -$22K – 571
2018
Q3 		$22K Sell
17,168
-64,382
-79% -$100K ﹤0.01% 335
2018
Q2 		$110K Buy
+81,550
New +$125K 0.01% 449

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's AST Position: Q4 2018 in Review

LMR Partners sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 17,168 shares — an estimated $22K sold.

LMR Partners first reported a position in AST in Q2 2018 and held it in 2 quarters. The position peaked at $110K in Q2 2018. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

  • LMR Partners reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
  • LMR Partners sold 17,168 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $22K.
  • LMR Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2018 and held it in 2 quarters.
  • LMR Partners's Asterias Biotherapeutics Inc. Series A position peaked at $110K in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on LMR Partners's 13F filing for Q4 2018, filed 14 Feb 2019.